This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Aortic Aortic valve Stenosis 
Frontiers in Cardiovascular Medicine
MARCH 9, 2025
Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.
52 
Heart BMJ
FEBRUARY 26, 2025
The sociodemographic characteristics of patients undergoing intervention for aortic stenosis (AS) in England, and the impact of COVID-19, is unknown. Background Health inequalities in cardiovascular care have been identified in the UK.
52 
Frontiers in Cardiovascular Medicine
DECEMBER 11, 2024
Bicuspid aortic valve (BAV), the most common congenital cardiac anomaly, predisposes individuals to aortic stenosis and regurgitation due to valve degeneration.
52 
JAMA Cardiology
FEBRUARY 11, 2025
This Viewpoint advocates for prompt aortic valve replacement (rather than clinical surveillance) as the default strategy for patients with asymptomatic severe aortic stenosis.
98 
JAMA Cardiology
OCTOBER 15, 2024
This narrative review analyzes associations among heart failure, aortic stenosis, and aortic valve replacement.
95 
Frontiers in Cardiovascular Medicine
MARCH 20, 2025
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aortic valve system (Xcor system, Saint Medical Technology, Inc.,
52 
Frontiers in Cardiovascular Medicine
JANUARY 16, 2025
Calcific aortic valve disease (CAVD) is a common cardiovascular condition in the elderly population. Research has shown that lncRNAs participate in the pathological process underlying CAVD by regulating osteogenic differentiation and inflammatory response of valve interstitial cells.
52 
Open Heart
MARCH 3, 2025
Background In congenital aortic stenosis (CAS), commissurotomy is an option in patients not suitable to receive a valve prosthesis. However, there is often a need for future additional interventions on the aortic valve. The fate of the aortic valve is, however, essentially unknown.
52 
Heart BMJ
FEBRUARY 12, 2025
Background Bicuspid aortic valve (BAV) is the most common congenital heart defect in adults, often leading to complications such as thoracic aortic aneurysms and aortic stenosis. While BAV is frequently associated with 22q11.2 This study is aimed to assess the role of rare 22q11.2 region (18–24 Mb).
52 
Cardiology Update
FEBRUARY 11, 2024
The NOTION trial, a pioneering study, sought to compare the long-term clinical and bioprosthesis outcomes of Transcatheter Aortic Valve Implantation (TAVI) versus Surgical Aortic Valve Replacement (SAVR) in patients with severe aortic valve stenosis (AS) at lower surgical risk.
124 
Heart BMJ
FEBRUARY 26, 2025
A significant proportion of patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) have concomitant coronary artery disease (CAD). The best way to treat these patients is contentious.
Open Heart
JANUARY 19, 2025
Background Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment approach remains uncertain. Methods A systematic literature review and meta-analysis was performed.
Frontiers in Cardiovascular Medicine
FEBRUARY 17, 2025
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).
52 
Heart BMJ
JANUARY 29, 2025
Background Subclinical leaflet thrombosis (SLT) is a common complication after transcatheter aortic valve replacement (TAVR). Methods This prospective cohort study consecutively enrolled patients with severe symptomatic aortic stenosis who underwent successful TAVR.
52 
DAIC
APRIL 25, 2024
Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly. Patients with aortic stenosis often have heart murmurs and experience debilitating symptoms including chest pain, dizziness, fatigue, shortness of breath and an irregular heartbeat.
105 
Heart BMJ
JULY 10, 2024
Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aortic valve replacement (TAVR).
98 
Frontiers in Cardiovascular Medicine
AUGUST 7, 2024
Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aortic valve replacement was the primary treatment option for severe AS for decades.
98 
American College of Cardiology
MAY 24, 2024
What is the relationship between aortic valve calcification (AVC) and aortic stenosis (AS) severity in patients with suspected low-flow low-gradient AS?
67 
DAIC
MARCH 25, 2024
The global, randomized trial ( envisiontrial.com ) will evaluate the safety and effectiveness of Abbott’s minimally invasive Navitor transcatheter aortic valve implantation (TAVI) system in approximately 1,500 patients at intermediate or low surgical risk with severe aortic stenosis (narrowing of the aortic valve).
115 
Med Page Today
OCTOBER 28, 2024
(MedPage Today) -- Transcatheter aortic valve replacement (TAVR) yielded clinical benefit when given early in the disease process while patients still had no symptoms or other indication for aortic valve replacement, according to the EARLY TAVR.
105 
DAIC
MARCH 31, 2025
Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Reardon, M.D.,
52 
Open Heart
JANUARY 8, 2024
Background A quarter of patients with severe aortic stenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. Only a select subset of these patients was recommended for aortic valve replacement (AVR) by the current American College of Cardiology/American Heart Association guidelines.
98 
JAMA Cardiology
JULY 16, 2024
This meta-analysis evaluates lipoprotein(a) concentrations and hemodynamic progression in patients with aortic stenosis.
79 
DAIC
JANUARY 29, 2024
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
111 
DAIC
MARCH 28, 2024
milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.
111 
Medical Xpress - Cardiology
SEPTEMBER 3, 2024
Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement for reducing death, stroke or rehospitalization in women with severe aortic stenosis, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
75 
The New England Journal of Medicine
JANUARY 15, 2025
Among patients with asymptomatic severe aortic stenosis, early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes.
74 
Open Heart
FEBRUARY 27, 2024
Objectives The clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer.
98 
Heart BMJ
FEBRUARY 26, 2025
In the 22 years since Professor Alain Cribier performed the first transcatheter aortic valve implantation (TAVI) in Rouen in France, treatment pathways for patients with aortic valve stenosis have evolved rapidly.
59 
American College of Cardiology
SEPTEMBER 18, 2024
The goal of the AVATAR trial was to evaluate aortic valve replacement (AVR) compared with conservative therapy among patients with asymptomatic severe aortic stenosis.
54 
DAIC
MARCH 4, 2025
The Most Common Form of HVD One of the most prevalent and serious forms of heart valve disease is aortic stenosis (AS), a condition characterized by the narrowing of the aortic valve opening, which affects approximately 5% of adults over 65a number expected to more than double by 2050.
52 
JAMA Cardiology
MARCH 25, 2025
This Viewpoint discusses the use of aortic valve intervention vs watchful waiting for patients with asymptomatic aortic stenosis.
41 
Journal of Cardiothoracic Surgery
APRIL 19, 2024
Patients with severe aortic stenosis (AS) and left ventricular (LV) dysfunction demonstrate improvement in left ventricular injection fraction (LVEF) after aortic valve replacement (AVR). The timing and magnit.
52 
Frontiers in Cardiovascular Medicine
FEBRUARY 6, 2025
IntroductionClinical evidence highlighting the efficacy and safety of transcatheter aortic valve replacement (TAVR) and the 2019 Food and Drug Administration (FDA) approval for TAVR in low-risk (younger) patients has created a demand for durable and long-lasting bioprosthetic heart valve (BHV) leaflet materials.
52 
Heart BMJ
APRIL 15, 2024
Objective Aortic stenosis (AS) shares pathophysiological similarities with atherosclerosis including active inflammation. CT attenuation of perivascular adipose tissue provides a measure of vascular inflammation that is linked to prognosis and has the potential to be applied to the aortic valve. HU, p=0.099).
52 
American College of Cardiology
MAY 29, 2024
In this week’s View, Dr. Eagle looks at the diagnostic value of aortic valve calcification levels in the assessment of low-gradient aortic stenosis.
49 
Frontiers in Cardiovascular Medicine
FEBRUARY 20, 2024
Background Closure of paravalvular leak (PVL) regurgitation after self-expandable (SE) transcatheter aortic valve implantation (TAVI) may be more challenging than after balloon-expandable (BE) valve implantation. MN, USA).
111 
American College of Cardiology
APRIL 8, 2024
The goal of the DEDICATE-DZHK6 trial was to evaluate transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis and low to intermediate surgical risk.
49 
Becker's Hospital Review - Cardiology
MAY 14, 2024
UPMC Harrisburg pioneers new transcatheter aortic valve replacement system, providing improved lifetime management for patients with aortic valve stenosis.
92 
Cardiovascular Diabetology
MARCH 4, 2025
Aortic valve calcification (AVC) is an underlying pathophysiological mechanism in aortic stenosis, which shares many risk factors with diabetes. However, the association between dysglycemia and early stages of.
52 
American College of Cardiology
APRIL 4, 2024
The goal of the VIVA trial was to evaluate transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis and a small aortic annulus.
43 
American College of Cardiology
FEBRUARY 26, 2025
In this weeks View, Dr. Eagle looks at the potential exposure-dependent protective effect of SGLT2 inhibitors on aortic valve stenosis progression.
52 
Journal of Cardiothoracic Surgery
JULY 29, 2024
Transcatheter aortic valve replacement (TAVR) has increased in utilization since its approval for management of aortic stenosis patients across all risk strata. We report a rare case of aortic valve leaflet av.
52 
Cardiology Update
FEBRUARY 26, 2024
Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aortic valve complex. Specifically, 14.2%
122
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content